Apr 19 |
Inhibikase Therapeutics files to sell common stock, warrants
|
Mar 29 |
Q4 2023 Inhibikase Therapeutics Inc Earnings Call
|
Mar 28 |
Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript
|
Mar 27 |
Inhibikase Therapeutics GAAP EPS of -$3.57 misses by $0.82, revenue of $0.26M in-line
|
Mar 27 |
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
|
Mar 7 |
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
|
Mar 5 |
HC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To Know
|
Feb 28 |
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
|
Feb 15 |
Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now
|
Feb 13 |
New Strong Buy Stocks for February 13th
|